Laekna Inc (2105)

Currency in HKD
13.14
+0.32(+2.50%)
Closed·
2105 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.3513.56
52 wk Range
8.1023.50
Key Statistics
Bid/Ask
13.02 / 13.14
Prev. Close
12.82
Open
12.6
Day's Range
12.35-13.56
52 wk Range
8.1-23.5
Volume
1.75M
Average Volume (3m)
2.41M
1-Year Change
3.7915%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2105 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.59
Upside
+94.75%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Laekna Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Laekna Inc Company Profile

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE122, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. It has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

Compare 2105 to Peers and Sector

Metrics to compare
2105
Peers
Sector
Relationship
P/E Ratio
−20.2x−15.7x−0.6x
PEG Ratio
−0.96−0.610.00
Price/Book
6.8x5.0x2.6x
Price / LTM Sales
1,050.0x15.7x3.3x
Upside (Analyst Target)
94.7%57.5%44.8%
Fair Value Upside
Unlock−10.5%5.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.59
(+94.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Aug 21, 2025
EPS / Forecast
-0.35 / --
Revenue / Forecast
4.51M / --
EPS Revisions
Last 90 days

2105 Income Statement

FAQ

What Is the Laekna (2105) Stock Price Today?

The Laekna stock price today is 13.14 HKD.

What Stock Exchange Does Laekna Trade On?

Laekna is listed and trades on the Hong Kong Stock Exchange.

What Is the Stock Symbol for Laekna?

The stock symbol for Laekna is "2105."

What Is the Laekna Market Cap?

As of today, Laekna market cap is 5.50B HKD.

What Is Laekna's Earnings Per Share (TTM)?

The Laekna EPS (TTM) is -0.65.

From a Technical Analysis Perspective, Is 2105 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Laekna Stock Split?

Laekna has split 0 times.

How Many Employees Does Laekna Have?

Laekna has 84 employees.

What is the current trading status of Laekna (2105)?

As of Feb 22, 2026, Laekna (2105) is trading at a price of 13.14 HKD, with a previous close of 12.82 HKD. The stock has fluctuated within a day range of 12.35 HKD to 13.56 HKD, while its 52-week range spans from 8.10 HKD to 23.50 HKD.

What Is Laekna (2105) Price Target According to Analysts?

The average 12-month price target for Laekna is 25.59 HKD, with a high estimate of 27.02 HKD and a low estimate of 24.16 HKD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +94.75% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.